KalVista Pharmaceuticals Acquired by Chiesi Group | Healthcare M&A Deal

Chiesi Group has acquired KalVista Pharmaceuticals, a pharmacy business in the United States, for $1.9B. KalVista Pharmaceuticals develops and commercializes Ekterly, the first FDA-approved oral treatment for acute swelling attacks in hereditary angioedema, supporting Chiesi Group’s rare disease portfolio. The tablet formulation is positioned as a dosing alternative to injectable HAE therapies, strengthening Chiesi Group acquisitions in specialty healthcare. The announced healthcare M&A is an add on acquisition by a strategic buyer, expanding Chiesi Group’s presence in pharmacy and rare disease.